Abstract #444: Molecular and clinical characterization of RICTOR (MTORC2) as a candidate oncogene in hepatocellular carcinoma
Augusto Villanueva(NYU Langone Health), Josep M. Llovet(Icahn School of Medicine at Mount Sinai), Clara Alsinet(Hospital Clínic de Barcelona), Beatriz Mínguez, Victoria Tovar(Hospital Clínic de Barcelona), Rad Savic, Derek Y. Chiang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Scott L. Friedman(Icahn School of Medicine at Mount Sinai), Myron Schwartz(Mount Sinai Medical Center), Anja Lechenmayer, Jordi Bruix(Hospital Clínic de Barcelona), Swan N. Thung(Icahn School of Medicine at Mount Sinai), Sara Toffanin(UiT The Arctic University of Norway), Yujin Hoshida(Broad Institute), Sasan Roayaie(White Plains Hospital), Helena Cornellà(Universitat de Barcelona)
Cancer Research
May 1, 2009
Cited by 0
Related Papers
Management of Hepatocellular Carcinoma: An Update Δσ
|Hepatology|2011|8.1k
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
|New England Journal of Medicine|1996|7.1k
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2021|6.6k
Management of Hepatocellular Carcinoma *
|Hepatology|2005|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k